Skip to Main

Andrew Rodriguez is a core member of the Health Care, Strategy, and Corporate Development practices at Boston Consulting Group.

Since joining BCG in 2002, Andrew has acquired broad health care experience in multiple sectors, focusing on biopharmaceuticals, vaccines, and global health. His clients have included multinational companies, foundations, and international organizations. As a core member of the firm’s global-health team, he has worked extensively on a range of assignments with the Bill & Melinda Gates Foundation.

Before joining BCG, Andrew was a strategic-planning manager with the worldwide beverage-company Diageo and cofounder of the business accelerator Techwell.

AREAS OF EXPERTISE

EDUCATION

  • MBA, Harvard Business School
  • BA, government, summa cum laude and Phi Beta Kappa, Dartmouth College

Publications and Videos

" "

Unlocking the Potential of AI in Drug Discovery

This report examines AI's potential in drug discovery, exploring key applications, assessing maturity, identifying barriers, and proposing solutions. It emphasizes the crucial role of health research funders in shaping this dynamic field to address urgent health needs equitably.

Ramping Up Vaccine Manufacturing in Africa | rectangle

Ramping Up Vaccine Manufacturing in Africa

Stakeholder support is crucial for ensuring that African vaccine-manufacturing companies can produce sufficient supply for the continent.
" "

Vaccines to tackle drug resistant infections

Antimicrobial resistance is difficult to combat. This report gives a comprehensive assessment of vaccine R&D potential against pathogens with high levels of AMR.
Close-up of face masks hanging with clothespins on a line

Transforming Clinical Trials with Real-World Evidence

Once a visionary ambition, synthetic control arms are poised to take off. Now is the time for pharma companies to identify opportunities and gain experience.
How-the-Pandemic-Is-Redefining-Clinical-Development-rectangle.jpg

How the Pandemic Is Redefining Clinical Development

Pharmaceutical companies can take four steps today to adapt their approach to clinical development and drive value by the end of 2020.
timelines-and-implications-for-covid-19-vaccines-rectangle-tcm9-246655.jpg

The Timelines and Implications for COVID-19 Vaccines

A 12- to 18-month timeline assumes that a vaccine progresses through all the various stages of testing without encountering significant issues.